|Bid||10.70 x 900|
|Ask||11.65 x 900|
|Day's Range||11.25 - 11.95|
|52 Week Range||2.10 - 12.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.83|
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 8.16% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of 45 cents. Xenon Pharmaceuticals shares have more than tripled since the beginning of the year. In the final minutes ...
Novel Epilepsy Product Candidates– XEN1101 and XEN901– Continue to Advance in the Clinic. New XEN1101 Phase 1 b TMS Pharmacodynamic Data to be Presented at upcoming European Congress on Epileptology. BURNABY, ...
BURNABY, British Columbia, Aug. 03, 2018-- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2018 financial and operating results ...
The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group
Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, announced today that it has entered into an at-the-market equity offering sales agreement with Jefferies and Stifel, effective as of July 11, 2018, under which Xenon may sell its common shares, from time to time, for up to $50.0 million in aggregate sales proceeds in "at the market" transactions. In connection with Xenon’s entry into the at-the-market equity offering sales agreement, its prior at-the-market equity offering sales agreement that it entered into with Stifel on May 8, 2018 was mutually terminated by Xenon and Stifel effective as of July 11, 2018.
BURNABY, British Columbia, June 01, 2018-- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present ...
LONDON, UK / ACCESSWIRE / May 17, 2018 / If you want access to our free research report on Xenon Pharma Inc. (NASDAQ: XENE), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=XENE as the Company's latest news hit the wire. On May 15, 2018, the Company announced that it has presented positive interim data from its ongoing XEN1101 Phase-1 clinical trial in a podium presentation at the 14th Eilat Conference on New Antiepileptic Drugs and Devices (Eilat) held in Madrid, Spain. Active-Investors.com is currently working on the research report for Coherus BioSciences, Inc. (NASDAQ: CHRS), which also belongs to the Healthcare sector as the Company Xenon Pharma.
The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) saw a modest uptick this week amid a slew of biotech earnings news flow and a deal announced in the space. Here's a compilation of key biotech ...
On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of 21 cents. Xenon Pharmaceuticals shares have more than doubled since the beginning of the year. In the final minutes ...
On March 7, 2018, Teva Pharmaceutical (TEVA) with Teva Canada and Xenon Pharmaceuticals (XENE) entered into a mutual agreement to terminate the collaborative development and license agreement they entered into in 2012 for the pain drug TV-45070. During Xenon Pharmaceuticals’ 2017 earnings results release, it announced the agreement termination news. On the day, TEVA stock rose ~0.8%, while Xenon stock rose ~7%. Teva Pharmaceutical stated that it was no longer interested in the development of TV-45070.
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Xenon Pharmaceuticals Inc. (NASDAQ: XENE ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018, at 4:30 PM Eastern ...
Xenon Pharmaceuticals (NASDAQ: XENE ) unveils its next round of earnings Wednesday. Get prepared with Benzinga's ultimate preview for Xenon Pharmaceuticals' Q4 earnings. Earnings and Revenue Analysts covering ...